The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females

  • Mok, Ji Oh (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Jung, Chan Hee (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Kim, Chul Hee (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Ryu, Chang Beom (Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital) ;
  • Kim, Yeo Joo (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Hospital) ;
  • Kim, Sang Jin (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Hospital) ;
  • Park, Hyeong Kyu (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital) ;
  • Suh, Kyo Il (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital) ;
  • Yoo, Myung Hi (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital) ;
  • Byun, Dong-Won (Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Hospital)
  • Received : 2012.02.11
  • Accepted : 2012.10.22
  • Published : 2013.11.01
⟨ Previous Next ⟩

Abstract

Background/Aims: This study was performed to compare the mucosal findings after esophagogastroduodenoscopy in two groups before and after the use of alendronate only and following administration of the enteric-coated alendronate (5 mg) and calcitriol ($0.5{\mu}g$) combined drug (Maxmarvil, Yuyu Co.). Methods: The study population consisted of 33 postmenopausal healthy female volunteers, aged 50 to 70 years (mean age, $58{\pm}5$) without gastrointestinal symptoms and with normal baseline endoscopic findings. Esophagogastroduodenoscopy was performed at baseline and was repeated 2 weeks later after daily intake of Maxmarvil (n = 17 subjects) or alendronate only (n = 16 subjects). Mucosal injury scores were reported by an endoscopist after 2 weeks of treatment with each medication schedule. Results: Esophageal mucosal injuries developed in two of 16 subjects in the alendronate only group and 0 of 17 in the Maxmarvil group. Gastric mucosal injuries developed in eight subjects in the alendronate group and four subjects in the Maxmarvil group; this difference was statistically significant. Conclusions: The mucosal damage scores for the alendronate group (total score 24) were significantly higher than those for the Maxmarvil group (total score 9) in the esophagus and stomach. Therefore, this study suggested that enteric-coated Maxmarvil is less harmful to gastrointestinal mucosa than alendronate, and may improve the tolerability of osteoporosis medication in clinical practice.

Keywords

References

  1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J 2001;94:569-573.
  2. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443. https://doi.org/10.1056/NEJM199511303332201
  3. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study: Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-468. https://doi.org/10.1007/PL00004171
  4. Luf kin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-322. https://doi.org/10.1007/BF01622190
  5. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009;122(2 Suppl):S22-S32.
  6. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-525. https://doi.org/10.1001/archinte.160.4.517
  7. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501. https://doi.org/10.1016/S0002-9343(96)00282-3
  8. Lanza F, Rack MF, Simon TJ, Lombardi A, Reyes R, Suryawanshi S. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 1998;93:753-757. https://doi.org/10.1111/j.1572-0241.1998.219_a.x
  9. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021. https://doi.org/10.1056/NEJM199610033351403
  10. Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997;102:489-491. https://doi.org/10.1016/S0002-9343(97)89446-6
  11. Kelly R, Taggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 1997;315:1235.
  12. Ribeiro A, DeVault KR, Wolfe JT 3rd, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47:525-528. https://doi.org/10.1016/S0016-5107(98)70256-1
  13. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377-1382.
  14. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008. https://doi.org/10.1007/s00198-004-1652-z
  15. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022. https://doi.org/10.4065/81.8.1013
  16. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000;42:175-195. https://doi.org/10.1016/S0169-409X(00)00061-2
  17. Shiraki M, Kushida K, Fukunaga M, et al. A doublemasked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis: the Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 1999;10:183-192. https://doi.org/10.1007/s001980050214
  18. Rhee Y, Kang M, Min Y, et al. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporos Int 2006;17:1801-1807. https://doi.org/10.1007/s00198-006-0200-4
  19. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148.
  20. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-912.
  21. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541. https://doi.org/10.1016/S0140-6736(96)07088-2
  22. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-492. https://doi.org/10.1056/NEJM199802193380801
  23. Maconi G, Bianchi Porro G. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-1890.
  24. Graham DY, Malaty HM. Drug-induced gastric ulcers are caused by more than just NSAIDs: alendronate gastric ulcers. Gastroenterology 1998;114(Suppl 1):A138.
  25. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-216. https://doi.org/10.1016/S0002-9343(03)00362-0
  26. Shiraki M, Kushida K, Fukunaga M, et al. A placebocontrolled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis: the Alendronate Research Group. Endocr J 1998;45:191-201. https://doi.org/10.1507/endocrj.45.191
  27. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-646. https://doi.org/10.1053/gast.2000.16518
  28. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000;95:634-640. https://doi.org/10.1111/j.1572-0241.2000.01835.x
  29. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001;161:107-110. https://doi.org/10.1001/archinte.161.1.107
  30. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002;97:58-64. https://doi.org/10.1111/j.1572-0241.2002.05446.x

Cited by

  1. Alendronate-induced unmasking or deterioration of coeliac disease: a case series vol.26, pp.1, 2013, https://doi.org/10.1007/s00198-014-2942-8
  2. Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Pacific Region (MUSIC OS-AP): Design of a multinational, prospective, observational study exam vol.3, pp.None, 2013, https://doi.org/10.1016/j.bonr.2015.09.002
  3. Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration vol.26, pp.1, 2013, https://doi.org/10.11005/jbm.2019.26.1.39